Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p

Pengfei Wu(Harbin Medical University), Jinquan Cai(Harbin Medical University), Qun Chen(Harbin Medical University), Bo Han(Harbin Medical University), Xiangqi Meng(Harbin Medical University), Yansheng Li(Tianjin Medical University General Hospital), Ziwei Li(Harbin Medical University), Ruijia Wang(Harbin Medical University), Lin Lin(Harbin Medical University), Chunbin Duan(Harbin Medical University), Chunsheng Kang(Tianjin Medical University General Hospital), Chuanlu Jiang(Harbin Medical University)
Nature Communications
May 3, 2019
Cited by 186Open Access
Full Text

Abstract

Long noncoding RNAs (lncRNAs) have emerged as new regulatory molecules implicated in diverse biological processes, including therapeutic resistance. However, the mechanisms underlying lncRNA-mediated temozolomide (TMZ) resistance in glioblastoma (GBM) remain largely unknown. To illustrate the role of lncRNA in TMZ resistance, we induce TMZ-resistant GBM cells, perform a lncRNA microarray of the parental and TMZ-resistant cells, and find an unreported lncRNA in GBM, lnc-TALC (temozolomide-associated lncRNA in glioblastoma recurrence), correlated with TMZ resistance via competitively binding miR-20b-3p to facilitate c-Met expression. A phosphorylated AKT/FOXO3 axis regulated lnc-TALC expression in TMZ-resistant GBM cells. Furthermore, lnc-TALC increased MGMT expression by mediating the acetylation of H3K9, H3K27 and H3K36 in MGMT promoter regions through the c-Met/Stat3/p300 axis. In clinical patients, lnc-TALC is required for TMZ resistance and GBM recurrence. Our results reveal that lnc-TALC in GBM could serve as a therapeutic target to overcome TMZ resistance, enhancing the clinical benefits of TMZ chemotherapy.


Related Papers

No related papers found

Powered by citation graph analysis